Journal of the Pediatric Infectious Diseases Society • Vol 12 • No 12
Efficacy, Safety, and Tolerability of Doravirine/Lamivudine/Tenofovir Disoproxil Fumarate Fixed-Dose Combination Tablets in Adolescents Living With HIV: Results Through Week 96 from IMPAACT 2014
October 2023 • Supattra Rungmaitree, Linda Aurpibul, Brookie M. Best, Xiang Li, Meredith G. Warshaw, Hong Wan, Nicole H. Tobin, Patricia Jumes, Randi Y. Leavitt, Ka…
Abstract Background IMPAACT 2014 study is a phase I/II, multicenter, open-label, nonrandomized study of doravirine (DOR) co-formulated with lamivudine (3TC) and tenofovir disoproxil fumarate (TDF) as fixed-dose combination (DOR FDC) in adolescents with HIV-1. We report the efficacy, safety, and tolerability of DOR FDC through 96 weeks. Methods Participants were adolescents aged 12 to <18 years who weighed at least 45 kg and who were either antiretroviral (ARV)-naïve or virologically suppressed without docum…